Model‐based analysis on systemic availability of co‐administered cannabinoids after controlled vaporised administration-Reference-Cited by-同舟云学术

Model‐based analysis on systemic availability of co‐administered cannabinoids after controlled vaporised administration

Published:2020-07 Issue:7 Volume:50 Page:846-853
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Liu Zheng¹²³^ORCID,Galettis Peter¹⁴,Broyd Samantha J.⁵,Hell Hendrika⁵,Greenwood Lisa‐Marie⁵,Krey Peter¹,Steigler Amy¹,Zhu Xiao⁶,Schneider Jennifer⁷,Solowij Nadia⁴⁵,Martin Jennifer H.¹⁴

Affiliation:

1. Schools of Medicine and Public HealthUniversity of Newcastle, Hunter Medical Research Institute Newcastle New South Wales Australia

2. Clinical Pharmacology, Department of MedicineThe Royal Children’s Hospital Melbourne Victoria Australia

3. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical SciencesMonash University Melbourne Victoria Australia

4. The Australian Centre for Cannabinoid Clinical and Research Excellence Newcastle New South Wales Australia

5. School of Psychology and Illawarra Health and Medical Research InstituteUniversity of Wollongong Wollongong New South Wales Australia

6. School of PharmacyUniversity of Otago Dunedin New Zealand

7. School of Biomedical Sciences and PharmacyUniversity of Newcastle, Hunter Medical Research Institute Newcastle New South Wales Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.14415

Reference27 articles.

1. Therapeutic Goods Administration Australian Government Department of Health. Access to medicinal cannabis products. [cited 2018 Feb]. Available from URL:https://www.tga.gov.au/access-medicinal-cannabis-products

2. Cannabinoids for Medical Use

3. The Pharmacologic and Clinical Effects of Medical Cannabis

4. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents

5. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis;Cannabis and Cannabinoid Research;2024-04-16

2. Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity;Drug Metabolism and Disposition;2024-01-29

3. Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial;Cannabis and Cannabinoid Research;2023-07-26

4. Measuring the diversity gap of cannabis clinical trial participants compared to people who report using cannabis;Scientific Reports;2023-06-16

5. Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular Users;Therapeutic Drug Monitoring;2023-05-04